Private Equity Archives - Gilde Healthcare

latest news
Private Equity

Gilde Healthcare sells RAD-x to a consortium of Swiss Life Asset Managers and Vesper Infrastructure Fund I

Gilde Healthcare’s Private Equity Fund (“Gilde Healthcare”), a specialized healthcare investor, has reached a binding agreement to sell its majority stake in RAD-x to a consortium of Swiss Life Asset Managers and Vesper Next Generation Infrastructure Fund I. Gilde Healthcare invested in and, together with the founders, set-up RAD-x in 2016. Since its inception and partnership with the first diagnostic...
18 maart 2024

Gilde Healthcare company NIZO acquires lactic acid facility and strengthens partnership with DSM-firmenich

test NIZO food research B.V. (“NIZO”) is proud to announce the signature of a long-term contract manufacturing partnership with dsm-firmenich. This strategic alliance encompasses the acquisition of the neighboring lactic acid facility from Vika Nutrition B.V., a Givaudan group company. With this move, NIZO widens its capabilities and secures the opportunity to develop the NIZO Food […]

Gilde Healthcare portfolio company Scharenborg Group appoints Johannes Schneider Littfeld as Chairman

test The Scharenborg Group, a leading footcare technology firm has appointed Johannes Schneider Littfeld as Chairman to the Advisory Board. Johannes is an experienced executive in the MedTech- and patient care industry. He spent 15 years in senior management of Otto Bock, the global leader in Orthopedic Technology. Johannes holds an MSc in Biomedical Engineering and […]

Gilde Healthcare invests in German precision surgical instruments contract manufacturer Koscher & Würtz

The acquisition of Koscher & Würtz represents a major step for Gilde Healthcare in forming a market leading instrument contract manufacturing group, following its initial investment in Chr. Diener, less than 18 months ago. Koscher & Würtz (K&W) will join as a group company next to Chr....

Gilde Healthcare company Noema Pharma raises CHF 103 million ($112 million)

Gilde Healthcare, a leading specialized healthcare investor, today announced that its portfolio company Noema Pharma, has raised an oversubscribed CHF 103 million ($112 million) Series B financing round from new and existing investors. Noema Pharma is a clinical-stage biopharma company targeting debilitating central nervous system (CNS) disorders....

Gilde Healthcare company Synexa Life Sciences celebrates its 20th anniversary

Two decades of advancing drug development programs through specialist biomarker and bioanalytical insights Synexa Life Sciences, a specialist biomarker and bioanalysis services provider, celebrates its 20th anniversary on March the 3rd 2023. Since its inception in 2003, Synexa Life Sciences has become a trusted partner to pharmaceutical,...

Gilde Healthcare sells its stake in Zetacom to facilitate a merger with Detron

The Private Equity fund of Gilde Healthcare, the leading European specialist healthcare investor, has reached an agreement to sell its majority stake in Zetacom to Avedon Capital, a leading mid-market private equity firm in the Benelux and DACH-region. Avedon will merge the company with Detron, an independent...

Gilde Healthcare neemt Sanquin Reagents over

Investeert in schaalvergroting en ontwikkeling nieuwe medische tests

Gilde Healthcare bolsters its Private Equity team in Frankfurt office

Dutch sector specialist Gilde Healthcare announces two new hires to its private equity team in Germany, following the recent close of its new €518m lower mid-market fund Gilde Healthcare Private Equity IV. With the recruitment of Martin von Berg as Investment Manager and Lara Hilgert as Investment...
Loading...
These were all messages
3fb453b822